Investors Reach $12M Deal In Biotech Stock-Drop Case
A shareholder class claiming biotech company NantKwest hid millions of dollars in executive compensation expenses from investors prior to its 2015 initial public offering has reached a $12 million proposed settlement...To view the full article, register now.
Already a subscriber? Click here to view full article